Table II.

PrognoScan^a microarray analysis of the prognostic value of GPBAR1 in human cancer. (High GPBAR1 gene expression predicted good prognosis in these datasets.)

Dataset	Cancer type	End point	Cohort	Contributor	Array type	Probe ID	No.	Cut point	Minimum P-value	Corrected P-value	ln (HR-high/HR-low)	COX P-value	ln (HR)	HR (95% CI)
GSE12417-GPL570	Blood	OS	AMLCG (2004)	Metzeler	HG-U133_Plus_2	1552501_a_at	79	0.27	0.114	–	−0.50	0.41	−0.28	0.76 (0.39–1.47)
GSE16581	Brain	OS	UCLA	Lee	HG-U133_Plus_2	1552501_a_at	67	0.25	0.021	0.275	−1.44	0.63	−0.81	0.44 (0.02–12.73)
GSE9195	Breast	DMFS	GUYT2	Loi	HG-U133_Plus_2	1552501_a_at	77	0.74	0.058	–	−15.50	1.00	−0.01	0.99 (0.06–16.54)
GSE17536	Colorectal	DFS	MCC	Smith	HG-U133_Plus_2	1552501_a_at	145	0.70	0.005	0.087	−1.39	0.12	−1.87	0.15 (0.01–1.62)
		OS					177	0.85	0.035	0.389	−0.94	0.25	−0.95	0.39 (0.08–1.96)
		DSS					177	0.84	0.023	0.295	−1.27	0.58	−0.52	0.60 (0.10–3.68)
GSE14333	Colorectal	DFS	Melbourne	Jorissen	HG-U133_Plus_2	1552501_a_at	226	0.85	0.076	–	−1.01	0.25	−0.17	0.85 (0.64–1.13)
GSE22138	Eye	DMFS	BRCIC	Laurent	HG-U133_Plus_2	1552501_a_at	63	0.81	0.015	0.216	−1.60	0.35	−6.72	0.00 (0–1599.31)
GSE2837	Head and neck	RFS	VUMC, VAMC, UTMDACC (1992–2005)	Chung	U133_X3P	Hs2.160954.1. S1_3p_s_at	28	0.25	0.117	–	−0.90	0.23	−3.90	0.02 (0.00–12.57)
GSE13213	Lung	OS	Nagoya (1995–1999, 2002–2004)	Tomida	G4112F	A_23_P400378	117	0.31	0.107	–	−0.47	0.97	−0.01	0.99 (0.62–1.59)
GSE31210	Lung	OS	NCCRI	Okayama	HG-U133_Plus_2	1552501_a_at	204	0.87	0.121	–	−1.45	0.81	0.05	1.05 (0.70–1.58)
		RFS					204	0.88	0.052	–	−1.30	0.48	−0.11	0.90 (0.67–1.21)
GSE17537	Colorectal	DSS	VMC	Smith	HG-U133_Plus_2	1552501_a_at	49	0.90	0.151	–	−15.26	0.87	0.30	1.35 (0.04–44.67)
GSE8894	Lung	RFS	Seoul (1995–2005)	Lee	HG-U133_Plus_2	1552501_a_at	138	0.26	0.002	0.048b	−0.75	0.08	−10.60	0.00 (0.00–3.68)
GSE17710	Lung	OS U	NC	Wilkerson	Agilent-UNC-custom-4X44K	25074	56	0.21	0.267	–	−0.44	0.83	−0.11	0.89 (0.32–2.53)
GSE9891	Ovarian	OS	AOCS, RBH, WH, NKI-AVL (1992–2006)	Tothill	HG-U133_Plus_2	1552501_a_at	278	0.74	0.024	0.304	−0.50	0.37	−0.35	0.71 (0.33–1.52)
GSE17260	Ovarian	PFS	Niigata (1997–2008)	Yoshihara	G4112A	A_23_P400378	110	0.70	0.077	–	−0.46	0.99	0.00	1.00 (0.58–1.73)
		OS					110	0.69	0.106	–	−0.57	0.56	−0.20	0.82 (0.41–1.63)
GSE19234	Skin	OS	NYU	Bogunovic	HG-U133_Plus_2	1552501_a_at	38	0.79	0.093	–	−1.20	0.31	−0.66	0.52 (0.14–1.86)

^awww.abren.net/PrognoScan/index.html.

^bP<0.05 is defined as statistically significant. OS, overall survival; DSS, disease-specific survival; DMFS, disease metastasis-free survival; RFS, relapse-free survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval.